References
- 1. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol. 2001; 57(5):365-376.
- 2. Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol. 2007; 39(7-8):1489-1499.1736907610.1016/j.biocel.2007.01.022
- 3. Ridings JE. The thalidomide disaster, lessons from the past. Methods Mol Biol. 2013; 947:575-586.
- 4. Eriksson T, Bjorkman S, Roth B, Hoglund P. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol. 2000; 52(7):807-817.10.1211/002235700177466010933131
- 5. Höglund P, Eriksson T, Björkman S. A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J Pharmacokinet and Biopharm. 1998; 26(4):363-383.10214558
- 6. Nishimura K, Hashimoto Y, Iwasaki S. (S)-form of alpha-methyl-N(α)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects. Chem Pharm Bull. 1994; 42(5):1157-1159.10.1248/cpb.42.11578069968
- 7. Wnendt S, Finkam M, Winter W, Ossig J, Raabe G, Zwingenberger K. Enantioselective inhibition of TNF-α release by thalidomide and thalidomide-analogues. Chirality. 1996; 8(5):390-396.10.1002/(SICI)1520-636X(1996)8:5<;390::AID-CHIR6>3.0.CO;2-I
- 8. Tian C, Xiu P, Meng Y, Zhao W, Wang Z, Zhou R. Enantiomerization mechanism of thalidomide and the role of water and hydroxide ions. Chemistry. 2012 5; 18(45):14305-14313.
- 9. Wolf C. Dynamic stereochemistry of chiral compounds: principles and applications: RSC Publishing; 2008. p. 29-135.
- 10. Sheskin J. Thalidomide in the Treatment of Lepra Reactions. Clin Pharmacol Ther. 1965; 6:303-306.14296027
- 11. Licht JD, Shortt J, Johnstone R. From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma. Cancer Cell. 2014; 25(1):9-11.10.1016/j.ccr.2013.12.019
- 12. Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol. 2005; 32(4 Suppl 5): S24-30.10.1053/j.seminoncol.2005.06.018
- 13. Łączkowski KZ, Baranowska-Łączkowska A. Recent studies on the thalidomide and its derivatives. Future Med Chem. 2018; 10(18) 2133-2136.
- 14. Jacques V, Czarnik AW, Judge TM, Van der Ploeg LH, DeWitt SH. Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs. Proc Natl Acad Sci USA. 2015; 112(12):E1471-1479.
- 15. Uttamsingh V, Gallegos R, Cheng C, Aslanian A, Liu JF, Tung R, Wu L. CTP-221, a deuterated S-enantiomer of lenalidomide, is greatly stabilized to epimerization and results in a more desirable pharmacokinetic profile than racemic lenalidomide. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3357. doi:10.1158/1538-7445.AM2013-3357 AACR; 2013.
- 16. Wu L, Aslanian AM, Liu JF, Hogan K, Tung R. CTP-221, a Deuterated S-Enantiomer of Lenalidomide, Possesses Significantly Enhanced Immunomodulatory and Anti-Proliferative Properties Relative to the R-Enantiomer and to Racemic Lenalidomide. Blood 2012, 120:2463.
- 17. Chung F, Palmer BD, Muller GW, Man HW, Kestell P, Baguley BC, et al. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Oncol Res. 2003; 14(2):75-82.10.3727/000000003108748621
- 18. Knabe J, Omlor G. [Synthesis of racemates and enantiomers of 3-alkylthalidomide analogs and determination of their absolute configuration]. Arch Pharm (Weinheim). 1989; 322(8):499-505.
- 19. Szabo ZI, Foroughbakhshfasaei M, Gal R, Horvath P, Komjati B, Noszal B, Tóth G. Chiral separation of lenalidomide by liquid chromatography on polysaccharide-type stationary phases and by capillary electrophoresis using cyclodextrin selectors. J Sep Sci. 2018; 41(6):1414-1423.10.1002/jssc.201701211
- 20. Szabo ZI, Szocs L, Horvath P, Komjati B, Nagy J, Janoska A, Noszal B., Toth G. Liquid chromatography with mass spectrometry enantioseparation of pomalidomide on cyclodextrin-bonded chiral stationary phases and the elucidation of the chiral recognition mechanisms by NMR spectroscopy and molecular modeling. J Sep Sci. 2016; 39(15):2941-2949.
- 21. Szabó ZI, Mohammadhassan F, Szőcs L, Nagy J, Komjáti B, Noszál B, Toth G. Stereoselective interactions and liquid chromatographic enantioseparation of thalidomide on cyclodextrin-bonded stationary phases. J Incl Phenom Macrocycl Chem. 2016; 85(3-4):227-236.
- 22. Del Valle EM. Cyclodextrins and their uses: a review. Process Biochem. 2004; 39(9):1033-1046.10.1016/S0032-9592(03)00258-9
- 23. Szabo ZI, Toth G, Volgyi G, Komjati B, Hancu G, Szente L, Beni S, Muntean DL, Noszal B. Chiral separation of asenapine enantiomers by capillary electrophoresis and characterization of cyclodextrin complexes by NMR spectroscopy, mass spectrometry and molecular modeling. J Pharm Biomed Anal. 2016; 5(117):398-404.
- 24. Szejtli J. Cyclodextrin inclusion complexes. Cyclodextrin technology: Springer; 1988. p. 79-185.
- 25. Tóth G, Mohácsi R, Rácz Á, Rusu A, Horváth P, Szente L, Béni Sz, Noszál B. Equilibrium and structural characterization of ofloxacin–cyclodextrin complexation. J Incl Phenom Macrocycl Chem. 2013; 77(1-4):291-300.
- 26. Armstrong DW, DeMond W. Cyclodextrin bonded phases for the liquid chromatographic separation of optical, geometrical, and structural isomers. J Chrom Sci. 1984; 22(9):411-415.
- 27. Kawaguchi Y, Tanaka M, Nakae M, Funazo K, Shono T. Chemically bonded cyclodextrin stationary phases for liquid chromatographic separation of aromatic compounds. Anal Chem. 1983; 55(12):1852-1857.
- 28. Hinze WL, Riehl TE, Armstrong DW, DeMond W, Alak A, Ward T. Liquid chromatographic separation of enantiomers using a chiral β-cyclodextrin-bonded stationary phase and conventional aqueous-organic mobile phases. Anal Chem. 1985;57(1):237-242.
- 29. GuangáLan W, KayáChee K, KeongáWong M, KeeáLee H, MináSin Y. Orthogonal array design as a chemometric method for the optimization of analytical procedures. Part 4. Mixed-level design and its application to the high-performance liquid chromatographic determination of polycyclic aromatic hydrocarbons. Analyst. 1995; 120(2):281-287.
- 30. Neumajer G, Sohajda T, Darcsi A, Toth G, Szente L, Noszal B, Béni Sz Chiral recognition of dapoxetine enantiomers with methylated-gamma-cyclodextrin: a validated capillary electrophoresis method. J Pharm Biomed Anal.. 2012; 62:42-47.
- 31. Wan HB, Lan WG, Wong MK, Mok CY. Orthogonal array designs for the optimization of liquid chromatographic analysis of pesticides. Anal Chim Acta. 1994; 289(3):371-380.